Testing a new immunotherapy drug for advanced lung cancer

Plain-English translation of NCT06767514 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated June 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This clinical trial is testing a new immunotherapy medication called ivonescimab to see if it works better than a standard immunotherapy drug called pembrolizumab for treating advanced lung cancer. Both medications work by helping your immune system recognize and fight cancer cells. The study will compare how well each medication works and how long patients survive.

Current immunotherapy treatments help some patients with advanced lung cancer live longer, but doctors are looking for treatments that work even better. This medication is being tested to see if it can offer patients a better chance at controlling their cancer and living longer.

Do you qualify?

You likely qualify if…

you are 18 years old or older
you have been diagnosed with advanced (stage 4) non-small cell lung cancer that has spread to other parts of your body
your cancer cells show high PD-L1 expression (a specific protein marker) confirmed by testing
you have not received any previous treatment for your advanced cancer
you are in good enough overall health to tolerate treatment (ECOG score 0-1)
you have a life expectancy of at least 3 months

You likely don't qualify if…

you have been treated for advanced lung cancer before
you have cancer that has spread to your brain, or you recently received radiation to your brain
you have a genetic mutation in your cancer that has an approved first-line treatment already available
you have a serious autoimmune disease or lung disease that requires ongoing treatment
you have had a major surgery or serious infection within the past 4 weeks

What participation looks like

If you join this study, you will be randomly assigned to receive either the new medication (ivonescimab) or the standard medication (pembrolizumab) as an intravenous injection. The study will track how well the medication works, how long you survive, and any side effects you experience. You will have regular follow-up visits and scans to monitor your cancer and overall health throughout the study.

AI-generated summary from trial data · Jun 9, 2026 · Not medical advice

Trial locations(270 sites)

United States

Clinical Study Site, Chandler, Arizona

Clinical Study Site, Phoenix, Arizona

Clinical Study Site, Hot Springs, Arkansas

Clinical Study Sites, Jonesboro, Arkansas

Clinical Study Site, Alameda, California